Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver

R. H. Wiltrout, R. B. Herberman, S. R. Zhang, M. A. Chirigos, J. R. Ortaldo, K. M. Green, J. E. Talmadge

Research output: Contribution to journalArticle

245 Citations (Scopus)

Abstract

Mice treated with anti-asialo GM1 (asGM1) serum exhibited increased formation of experimental metastases in lung and liver after i.v. challenge with B16 melanoma or Lewis lung carcinoma. This increased metastasis formation coincided with decreased splenic NK activity and increased survival of i.v. injected radiolabeled tumor cells. In contrast, the injection of mice with the pyran copolymer maleic anhydride divinyl ether (MVE-2) augmented NK activity in the spleen and significantly depressed the formation of experimental metastases in the lungs and liver. However, a single or double administration of anti-asGM1 antiserum to MVE-2-pretreated mice failed to inhibit the immunoprophylaxis associated with MVE-2 administration, although it did not decrease splenic NK activity and also increased the survival of i.v.-injected radiolabeled tumor cells. To address the mechanism for this dichotomy, we examined NK activity not only in the spleen but also in the blood, lungs, and livers of MVE-2-treated mice. Levels of NK activity in the lungs and liver were several-fold higher than those observed in spleen and blood. However, MVE-2-augmented NK activity in lung and liver was more resistant to depletion by the standard regimen of anti-asGM1 treatment than was NK activity in blood and spleen, and required two high-dose administrations of a higher titered antiserum for depletion of the augmented response. This high-dose regimen removed all detectable NK activity from the lung and liver, and concomitantly eliminated the metastasis-inhibiting effect of MVE-2. These data are consistent with a role for organ-associated NK cells in inhibiting metastasis formation during the extravasation and/or early postextravasation phases of the metastatic process. The results also suggest that biologic effects of NK activity in spleen and blood can be dissociated from those mediated by NK activity in other organs by use of different treatment regimens with anti-asGM1 serum. Finally, because NK activity in target organs can be augmented to an even greater extent than in the blood and spleen by at least some biologic response modifiers (BRMs), organ-associated NK activity should be considered as a possible mechanism for the therapeutic effects of BRM treatment.

Original languageEnglish (US)
Pages (from-to)4267-4275
Number of pages9
JournalJournal of Immunology
Volume134
Issue number6
StatePublished - Sep 25 1985

Fingerprint

Pyran Copolymer
Natural Killer Cells
Neoplasm Metastasis
Lung
Spleen
Liver
Immune Sera
Lewis Lung Carcinoma
Experimental Melanomas
Therapeutic Uses
Serum
Neoplasms

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Wiltrout, R. H., Herberman, R. B., Zhang, S. R., Chirigos, M. A., Ortaldo, J. R., Green, K. M., & Talmadge, J. E. (1985). Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. Journal of Immunology, 134(6), 4267-4275.

Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. / Wiltrout, R. H.; Herberman, R. B.; Zhang, S. R.; Chirigos, M. A.; Ortaldo, J. R.; Green, K. M.; Talmadge, J. E.

In: Journal of Immunology, Vol. 134, No. 6, 25.09.1985, p. 4267-4275.

Research output: Contribution to journalArticle

Wiltrout, RH, Herberman, RB, Zhang, SR, Chirigos, MA, Ortaldo, JR, Green, KM & Talmadge, JE 1985, 'Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver', Journal of Immunology, vol. 134, no. 6, pp. 4267-4275.
Wiltrout RH, Herberman RB, Zhang SR, Chirigos MA, Ortaldo JR, Green KM et al. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. Journal of Immunology. 1985 Sep 25;134(6):4267-4275.
Wiltrout, R. H. ; Herberman, R. B. ; Zhang, S. R. ; Chirigos, M. A. ; Ortaldo, J. R. ; Green, K. M. ; Talmadge, J. E. / Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. In: Journal of Immunology. 1985 ; Vol. 134, No. 6. pp. 4267-4275.
@article{217296a7061c44b3bd8b605050604e67,
title = "Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver",
abstract = "Mice treated with anti-asialo GM1 (asGM1) serum exhibited increased formation of experimental metastases in lung and liver after i.v. challenge with B16 melanoma or Lewis lung carcinoma. This increased metastasis formation coincided with decreased splenic NK activity and increased survival of i.v. injected radiolabeled tumor cells. In contrast, the injection of mice with the pyran copolymer maleic anhydride divinyl ether (MVE-2) augmented NK activity in the spleen and significantly depressed the formation of experimental metastases in the lungs and liver. However, a single or double administration of anti-asGM1 antiserum to MVE-2-pretreated mice failed to inhibit the immunoprophylaxis associated with MVE-2 administration, although it did not decrease splenic NK activity and also increased the survival of i.v.-injected radiolabeled tumor cells. To address the mechanism for this dichotomy, we examined NK activity not only in the spleen but also in the blood, lungs, and livers of MVE-2-treated mice. Levels of NK activity in the lungs and liver were several-fold higher than those observed in spleen and blood. However, MVE-2-augmented NK activity in lung and liver was more resistant to depletion by the standard regimen of anti-asGM1 treatment than was NK activity in blood and spleen, and required two high-dose administrations of a higher titered antiserum for depletion of the augmented response. This high-dose regimen removed all detectable NK activity from the lung and liver, and concomitantly eliminated the metastasis-inhibiting effect of MVE-2. These data are consistent with a role for organ-associated NK cells in inhibiting metastasis formation during the extravasation and/or early postextravasation phases of the metastatic process. The results also suggest that biologic effects of NK activity in spleen and blood can be dissociated from those mediated by NK activity in other organs by use of different treatment regimens with anti-asGM1 serum. Finally, because NK activity in target organs can be augmented to an even greater extent than in the blood and spleen by at least some biologic response modifiers (BRMs), organ-associated NK activity should be considered as a possible mechanism for the therapeutic effects of BRM treatment.",
author = "Wiltrout, {R. H.} and Herberman, {R. B.} and Zhang, {S. R.} and Chirigos, {M. A.} and Ortaldo, {J. R.} and Green, {K. M.} and Talmadge, {J. E.}",
year = "1985",
month = "9",
day = "25",
language = "English (US)",
volume = "134",
pages = "4267--4275",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "6",

}

TY - JOUR

T1 - Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver

AU - Wiltrout, R. H.

AU - Herberman, R. B.

AU - Zhang, S. R.

AU - Chirigos, M. A.

AU - Ortaldo, J. R.

AU - Green, K. M.

AU - Talmadge, J. E.

PY - 1985/9/25

Y1 - 1985/9/25

N2 - Mice treated with anti-asialo GM1 (asGM1) serum exhibited increased formation of experimental metastases in lung and liver after i.v. challenge with B16 melanoma or Lewis lung carcinoma. This increased metastasis formation coincided with decreased splenic NK activity and increased survival of i.v. injected radiolabeled tumor cells. In contrast, the injection of mice with the pyran copolymer maleic anhydride divinyl ether (MVE-2) augmented NK activity in the spleen and significantly depressed the formation of experimental metastases in the lungs and liver. However, a single or double administration of anti-asGM1 antiserum to MVE-2-pretreated mice failed to inhibit the immunoprophylaxis associated with MVE-2 administration, although it did not decrease splenic NK activity and also increased the survival of i.v.-injected radiolabeled tumor cells. To address the mechanism for this dichotomy, we examined NK activity not only in the spleen but also in the blood, lungs, and livers of MVE-2-treated mice. Levels of NK activity in the lungs and liver were several-fold higher than those observed in spleen and blood. However, MVE-2-augmented NK activity in lung and liver was more resistant to depletion by the standard regimen of anti-asGM1 treatment than was NK activity in blood and spleen, and required two high-dose administrations of a higher titered antiserum for depletion of the augmented response. This high-dose regimen removed all detectable NK activity from the lung and liver, and concomitantly eliminated the metastasis-inhibiting effect of MVE-2. These data are consistent with a role for organ-associated NK cells in inhibiting metastasis formation during the extravasation and/or early postextravasation phases of the metastatic process. The results also suggest that biologic effects of NK activity in spleen and blood can be dissociated from those mediated by NK activity in other organs by use of different treatment regimens with anti-asGM1 serum. Finally, because NK activity in target organs can be augmented to an even greater extent than in the blood and spleen by at least some biologic response modifiers (BRMs), organ-associated NK activity should be considered as a possible mechanism for the therapeutic effects of BRM treatment.

AB - Mice treated with anti-asialo GM1 (asGM1) serum exhibited increased formation of experimental metastases in lung and liver after i.v. challenge with B16 melanoma or Lewis lung carcinoma. This increased metastasis formation coincided with decreased splenic NK activity and increased survival of i.v. injected radiolabeled tumor cells. In contrast, the injection of mice with the pyran copolymer maleic anhydride divinyl ether (MVE-2) augmented NK activity in the spleen and significantly depressed the formation of experimental metastases in the lungs and liver. However, a single or double administration of anti-asGM1 antiserum to MVE-2-pretreated mice failed to inhibit the immunoprophylaxis associated with MVE-2 administration, although it did not decrease splenic NK activity and also increased the survival of i.v.-injected radiolabeled tumor cells. To address the mechanism for this dichotomy, we examined NK activity not only in the spleen but also in the blood, lungs, and livers of MVE-2-treated mice. Levels of NK activity in the lungs and liver were several-fold higher than those observed in spleen and blood. However, MVE-2-augmented NK activity in lung and liver was more resistant to depletion by the standard regimen of anti-asGM1 treatment than was NK activity in blood and spleen, and required two high-dose administrations of a higher titered antiserum for depletion of the augmented response. This high-dose regimen removed all detectable NK activity from the lung and liver, and concomitantly eliminated the metastasis-inhibiting effect of MVE-2. These data are consistent with a role for organ-associated NK cells in inhibiting metastasis formation during the extravasation and/or early postextravasation phases of the metastatic process. The results also suggest that biologic effects of NK activity in spleen and blood can be dissociated from those mediated by NK activity in other organs by use of different treatment regimens with anti-asGM1 serum. Finally, because NK activity in target organs can be augmented to an even greater extent than in the blood and spleen by at least some biologic response modifiers (BRMs), organ-associated NK activity should be considered as a possible mechanism for the therapeutic effects of BRM treatment.

UR - http://www.scopus.com/inward/record.url?scp=0021870917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021870917&partnerID=8YFLogxK

M3 - Article

C2 - 3989307

AN - SCOPUS:0021870917

VL - 134

SP - 4267

EP - 4275

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 6

ER -